Jonathan Badrock
Overview
Explore the profile of Jonathan Badrock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez-Gili L, Pechlivanis A, McDonald J, Begum S, Badrock J, Dyson J, et al.
Gut Microbes
. 2023 May;
15(1):2208501.
PMID: 37191344
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with ursodeoxycholic acid (UDCA) as first-line treatment. Poor response to UDCA is associated with a higher risk of progressing to...
2.
Mulcahy V, Liaskou E, Martin J, Kotagiri P, Badrock J, Jones R, et al.
Hepatol Commun
. 2023 Apr;
7(4).
PMID: 37026715
Background Aims: In patients with primary biliary cholangitis (PBC), the serum liver biochemistry measured during treatment with ursodeoxycholic acid-the UDCA response-accurately predicts long-term outcome. Molecular characterization of patients stratified by...
3.
Merrick S, Nankivell M, Quartagno M, Clarke C, Joharatnam-Hogan N, Waddell T, et al.
Contemp Clin Trials
. 2022 Dec;
124:107030.
PMID: 36519749
Background: Immune checkpoint inhibitors (ICI) have revolutionised treating advanced cancers. ICI are administered intravenously every 2-6 weeks for up to 2 years, until cancer progression/unacceptable toxicity. Physiological efficacy is observed...
4.
Barkauskas C, Mylonakis E, Poulakou G, Young B, Vock D, Siegel L, et al.
Ann Intern Med
. 2022 Aug;
175(9):1266-1274.
PMID: 35939810
Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. Objective: To investigate if ensovibep, in addition...
5.
Clamp A, James E, McNeish I, Dean A, Kim J, ODonnell D, et al.
Lancet Oncol
. 2022 Jun;
23(7):919-930.
PMID: 35690073
Background: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with...
6.
Barron-Millar B, Ogle L, Mells G, Flack S, Badrock J, Sandford R, et al.
Hepatology
. 2021 Jun;
74(6):3269-3283.
PMID: 34129689
Background And Aims: Stratified therapy has entered clinical practice in primary biliary cholangitis (PBC), with routine use of second-line therapy in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA). The...
7.
Rice S, Albani V, Minos D, Fattakhova G, Mells G, Carbone M, et al.
Clin Gastroenterol Hepatol
. 2020 Jun;
19(4):768-776.e10.
PMID: 32562892
Background & Aims: There have been few high-quality studies of the costs, preference-based health-related quality of life (HRQoL) and cost effectiveness of treatments for primary biliary cholangitis (PBC). We aimed...
8.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al.
Lancet Gastroenterol Hepatol
. 2018 Jul;
3(9):626-634.
PMID: 30017646
Background: Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months...